GlassScriptPhysician profile
Susan Aliff
NPI 1013348556
$1,917.89
in general payments reported to CMS, 2019-2025
34 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.72 · 2022: $17.53 · 2023: $56.44 · 2024: $222 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.24 |
| Education | $311.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $234.84 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Gilead Sciences, INC. | $155.92 | 2025 | Trodelvy |
| Incyte Corporation | $129.07 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Glaxosmithkline, LLC. | $119.07 | 2025 | Zejula |
| Abbvie INC. | $109.27 | 2024-2025 | |
| Daiichi Sankyo INC. | $108.63 | 2024-2025 | Enhertu, Datroway |
| Seagen INC. | $99.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $97.46 | 2025 | Calquence |
| Celgene Corporation | $85.94 | 2024-2025 | Reblozyl |
| Pfizer INC. | $77.40 | 2025 | |
| Novartis Pharmaceuticals Corporation | $66.56 | 2025 | |
| Pharmacosmos Therapeutics INC. | $62.97 | 2024-2025 | Monoferric |
| Amgen INC. | $62.20 | 2023-2024 | Prolia, Evenity |
| E.R. Squibb & Sons, L.L.C. | $56.79 | 2025 | Opdualag |
| Merck Sharp & Dohme LLC | $50.06 | 2024-2025 | Keytruda |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $41.11 | 2024-2025 | Udenyca, Loqtorzi |
| Caris Mpi, INC. | $35.38 | 2025 | Mi Cancer Seek |
| Eisai INC. | $32.79 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.92 | 2025 | Hyqvia |
| Ultragenyx Pharmaceutical INC. | $24.85 | 2023 | |
| Genmab U.S., INC. | $22.96 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.06 | 2025 | Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $21.73 | 2025 | |
| Servier Pharmaceuticals LLC | $20.05 | 2025 | |
| Tersera Therapeutics LLC | $19.42 | 2025 | Zoladex |
| Boston Scientific Corporation | $17.53 | 2022 | |
| Stemline Therapeutics INC. | $17.35 | 2025 | Orserdu |
| Puma Biotechnology, INC. | $16.54 | 2025 | |
| Aveo Pharmaceuticals, INC. | $16.31 | 2025 | |
| Shield Therapeutics INC | $15.24 | 2024 | |
| Array Biopharma INC | $14.42 | 2025 | Tukysa, Braftovi, Mektovi |
| Beone Medicines USA, INC. | $13.50 | 2025 | Brukinsa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.72 | 2021 | |
| Iovance Biotherapeutics, INC. | $8.83 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Aliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.